Definition

An orally bioavailable inhibitor of the anti-apoptotic protein myeloid cell leukemia 1 (MCL1; induced myeloid leukemia cell differentiation protein; myeloid cell leukemia-1; Mcl-1; Bcl2-L-3), with potential antineoplastic activity. Upon oral administration, the MCL1 inhibitor PRT1419 targets and binds to MCL1. This prevents the binding of MCL1 to and inactivation of certain pro-apoptotic proteins. This promotes apoptosis of cells overexpressing MCL1. MCL1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.